Statins in the intensive care unit
Authors:
- 1 August 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 12 (4) , 309-314
Abstract
Statins are effective lipid-lowering agents used extensively in medical practice. This review summarizes the evidence for statin treatment of cardiovascular patients in the intensive care unit and briefly discusses the role of statins in prevention and treatment of sepsis as a potential future application of statins in critical care. Recent studies have extended the use of statin therapy to the acute manifestations of cardiovascular disease and have suggested cholesterol-independent therapeutic benefits, termed pleiotropic effects, which have added a wide scope of potential targets for statin therapy. Statin therapy should be continued in intensive-care patients in whom statin therapy is warranted due to underlying cardiovascular disease or significant risk thereof. In acute coronary syndromes, statin therapy should be initiated within 24-96 h regardless of pretreatment cholesterol levels. Patients undergoing vascular surgery should receive peri-operative statin therapy. Placebo-controlled clinical trials are required to consolidate the experimental and observational evidence for prevention and treatment of sepsis.Keywords
This publication has 77 references indexed in Scilit:
- Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the RatCirculation, 2005
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart FailureCirculation, 2005
- Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary DiseaseCirculation, 2005
- Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architecturesCurrent Opinion in Structural Biology, 2001
- Statins as a newly recognized type of immunomodulatorNature Medicine, 2000
- Inhibition of Monocyte Chemotactic Protein-1 Synthesis by StatinsLaboratory Investigation, 2000
- HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With HypercholesterolemiaJACC, 1997
- Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitroImmunopharmacology, 1996
- Regulation of the mevalonate pathwayNature, 1990